DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results for the quarter and year ended December 31, 2020. Fourth Quarter and Full Year 2020 Financial Highlights Billable sample volume of approximately 8,300 for the fourth quarter of 2020, a 69% increase compared to approximately 4,900 recorded for the fourth quarter of 2019 and a 24% sequential increase ove

DermTech Reports Fourth Quarter and Full Year 2020 Financial Results

Etsy

Skillz

The wind is definitely at the backs of these high-flying stocks.

3 Fantastic Growth Stocks That Could Easily Make You a Fortune

This high-flying healthcare stock should have more room to run.

Why DermTech Stock Is a Buy Right Now

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that four of its abstracts were selected by the Society for Investigative Dermatology (“SID”) for presentation at the SID Virtual Meeting, taking place May 3-8, 2021. The SID is committed to the advancement of skin health and disease through education, advocacy and scholarly exchange of scientific information. In addit

DermTech Abstracts Selected to Present at Society of Investigative Dermatology Virtual Meeting

Dermtech stock is up over 130% so far in 2021, and increased insurance acceptance is just one reason it could be a five-bagger in the next five years.

It's Already Doubled in 2021, and This Healthcare Juggernaut Is Just Getting Started

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its fourth quarter 2020 financial results after the market closes on Thursday, March 4, 2021. In conjunction with such release, DermTech plans to host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. Int

DermTech to Announce Fourth Quarter 2020 Financial Results on March 4, 2021

Shares of the skin-cancer genomics company gained as it opened up a new customer base.

Why DermTech Stock Jumped Today

DermTech Inc (NASDAQ: DMTK) shares were soaring to a new high Thursday after the company unveiled a contract with Blue Cross Blue Shield of Texas for its melanoma gene express test. What Happened: La Jolla, California-based DermTech, a precision dermatology company, said it has entered into a contract with the BCBSTX for making its pigmented lesion assay, or PLA, which became available to the health insurer's 6 million members in the state of Texas Feb. 1.

Dermtech Rallies To Record High On Health Insurance Contract For Skin Cancer Detection Test

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it has contracted, effective 2/1/2021, with Blue Cross Blue Shield of Texas (“BCBSTX”) to make DermTech's Pigmented Lesion Assay (“PLA”) available to its approximately 6 million members in the State of Texas. DermTech's gene expression-based PLA for the early detection of melanoma is now available as an in-network opti

DermTech Enters Into Agreement with Blue Cross Blue Shield of Texas

Investor excitement mounted around the skin-care detection specialist.

Why DermTech Stock Gained 26% Last Month

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of Dr. Lisa Beck and Dr. George Han to its Scientific Advisory Board (“SAB”). The SAB provides important support and advice to DermTech, which advances its research and development of skin cancer and skin disease tests and treatment. The experience of each member of the SAB in dermatology, skin cancer, ge

DermTech Announces New Scientific Advisory Board Members

They don't need a short squeeze to skyrocket.

3 Unstoppable Stocks That'll Crush GameStop in 2021

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 1:00 p.m. Eastern Time. Interested parties may access a live webcast of the presentation and, for 90 days following the BTIG Conference, an archived webcas

DermTech Management to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Fiverr

Social Capital Hedosophia Holdings Corp. V

The shortest month is a great time to go long with these great stocks.

Got $2,000? Here Are 3 Top Growth Stocks to Buy in February

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its support and presentation in the Melanoma Research Foundation's (“MRF”) “Ask the Expert” webinar series throughout the month of January. The events featured leading dermatologists and industry experts to increase awareness and education on melanoma. A key focus of the series was the importance of early detection of

DermTech Featured in Melanoma Research Foundation Weekly “Ask the Expert” Facebook Live Events Alongside Notable Industry Scientists

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the 2021 Dermatology Summit virtual conference (the “Dermatology Summit”) on Jan. 8, 2021. The Dermatology Summit uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnershi

DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021

Conagra Brands

Aldeyra Therapeutics

Fate Therapeutics

Generation Bio

Mersana Therapeutics

Old Republic International

REV Group

B. Riley Financial

Sprout Social

York Water

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there has been due to the pandemic resurgence and political issues.

Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that SKIN has published the results of a large registry study finding that the evaluation of genomic atypia using DermTech's Pigmented Lesion Assay (the “PLA”) may be a superior approach to guide treatment decisions and manage pigmented lesions, when compared to visual assessment of pigmented lesions. Melanoma is a lif

DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that non-invasive genomic patch testing for melanoma, like DermTech's Pigmented Lesion Assay (“PLA”), has received a recommendation from the National Comprehensive Cancer Network® (“NCCN”). The recommendation indicates that there is uniform NCCN consensus that the intervention is appropriate. The NCCN Clinical Practice

DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the closing of its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share. DermTech's aggregate gross proceeds from the of

DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 per share. DermTech's gross proceeds from the offering are expected to be approximately $125 million, before deducting underwriting discounts and commissions and offering expen

DermTech Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, DermTech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. All of the shares in the offering will be sold by DermTec

DermTech Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Ray Akhavan to the role of General Counsel. Akhavan will serve on the executive leadership team and have responsibility for all legal, intellectual property and compliance matters. “Ray is the perfect fit for DermTech's general counsel role given his balanced experience in medical and consumer genomi

DermTech Announces Appointment of General Counsel

The biotech's skin cancer diagnostic tool is a significant improvement over the standard of care.

Here's Why You Should Really Own DermTech Stock in 2021

The company's genomic test for melanoma won another positive coverage decision.

News for DermTech Inc Stock (DMTK)